These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31453773)

  • 1. Low-frequency variants at the
    Claudio-Campos K; Moneró-Paredes M; Hernández E; Renta J; Duconge J
    Pharmacogenomics; 2019 Aug; 20(12):891-902. PubMed ID: 31453773
    [No Abstract]   [Full Text] [Related]  

  • 2. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.
    Claudio-Campos KI; González-Santiago P; Renta JY; Rodríguez J; Carrasquillo K; Gaedigk A; Roche A; Ducongé J
    Pharmacogenomics; 2019 Jan; 20(1):3-8. PubMed ID: 30518301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.
    Claudio-Campos K; Labastida A; Ramos A; Gaedigk A; Renta-Torres J; Padilla D; Rivera-Miranda G; Scott SA; Ruaño G; Cadilla CL; Duconge-Soler J
    Front Pharmacol; 2017; 8():347. PubMed ID: 28638342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin.
    Pavani A; Naushad SM; Stanley BA; Kamakshi RG; Abinaya K; Amaresh Rao M; Uma A; Kutala VK
    Pharmacogenomics; 2015; 16(4):393-400. PubMed ID: 25823787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran.
    Fereidouni M; Moossavi M; Kazemi T; Nouranihassankiade S; Asghari A
    J Cell Biochem; 2019 Jun; 120(6):9588-9593. PubMed ID: 30525241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.
    Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A
    Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.
    Hernandez W; Aquino-Michaels K; Drozda K; Patel S; Jeong Y; Takahashi H; Cavallari LH; Perera MA
    Transl Res; 2015 Jun; 165(6):651-7. PubMed ID: 25499099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
    Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
    Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population.
    Chowdhury ZS; Shahjin F; Akter F; Ahmed M; Islam MS; Bin Sayeed MS; Islam R; Hasnat A
    Pak J Pharm Sci; 2017 Mar; 30(2):341-346. PubMed ID: 28649054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy.
    Jarrar YB; Lee SJ
    Drug Metabol Drug Interact; 2014; 29(4):211-20. PubMed ID: 24825094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.
    Karnik ND; Sridharan K; Tiwari D; Gupta V
    Indian J Pharmacol; 2014; 46(5):549-50. PubMed ID: 25298588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.
    Flora DR; Rettie AE; Brundage RC; Tracy TS
    J Clin Pharmacol; 2017 Mar; 57(3):382-393. PubMed ID: 27539372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
    Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
    Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
    Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
    Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.